# Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

> **NCT04347681** · PHASE2 · COMPLETED · sponsor: **King Fahad Specialist Hospital Dammam** · enrollment: 575 (actual)

## Conditions studied

- Convalescent Plasma for COVID 19

## Interventions

- **OTHER:** convalescent plasma from recovered COVID 19 donor

## Key facts

- **NCT ID:** NCT04347681
- **Lead sponsor:** King Fahad Specialist Hospital Dammam
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-18
- **Primary completion:** 2020-11-01
- **Final completion:** 2020-11-16
- **Target enrollment:** 575 (ACTUAL)
- **Last updated:** 2021-11-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04347681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04347681, "Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04347681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*